Quest Diagnostics (DGX) Tops Q1 EPS by 5c; offers guidance

Quest Diagnostics (NYSE: DGX) reported Q1 EPS of $2.21, $0.05 better than the analyst estimate of $2.16. Revenue for the quarter came in at $2.65 billion versus the consensus estimate of $2.64 billion.

GUIDANCE:

Quest Diagnostics sees FY2025 EPS of $9.55-$9.80, versus the consensus of $9.69. Quest Diagnostics sees FY2025 revenue of $10.7-10.85 billion, versus the consensus of $10.78 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Bernstein SocGen Group Upgrades X-Fab Silicon Foundries SE (XFAB:FP) to Outperform
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Barclays Starts DKSH Holding AG (DKSH:SW) at Overweight